Your session is about to expire
← Back to Search
Vitamin D Supplement
(CKD) stages III-V and non -CKD patients for Chronic Kidney Disease
N/A
Waitlist Available
Led By Barry M Wall, MD
Research Sponsored by Memphis VA Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
* age 18-85 years; CKD stage III or V; serum 25(OH)D level ≤ 30ng/ml, and serum PTH levels \> 70 pg/ml within the last 6 months, informed Consent.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Awards & highlights
Summary
To determine whether or not chronic kidney disease (CKD), stages III-V and ESRD , is associated with altered vitamin D metabolism related to fibroblast growth factor-23 (FGF-23) stimulation of Cyp24 and whether they have resistance to elevations of 25 Hydroxyvitamin D (25(OH)D3) after cholecalciferol supplementation. To determine if such resistance is related to enhanced catabolism of (25(OH)related to elevated levels of FGF-23.
Eligible Conditions
- Chronic Kidney Disease
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 8 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Kidney Failure, Chronic
Trial Design
1Treatment groups
Experimental Treatment
Group I: (CKD) stages III-V and non -CKD patientsExperimental Treatment1 Intervention
We recruited patients with wide range of eGFR
Find a Location
Who is running the clinical trial?
Memphis VA Medical CenterLead Sponsor
7 Previous Clinical Trials
1,670 Total Patients Enrolled
Barry M Wall, MDPrincipal InvestigatorMemphis , TN ,VAMC
HALA M Alshayeb, MDPrincipal InvestigatorUTHSC, UCH
Share this study with friends
Copy Link
Messenger